Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-08
DOI
10.1038/s41467-020-20493-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma
- (2020) Jack V.W. Bacon et al. Clinical Genitourinary Cancer
- Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
- (2020) Cameron Herberts et al. EUROPEAN UROLOGY
- Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
- (2019) Nora Sundahl et al. EUROPEAN UROLOGY
- Genomic correlates of response to immune checkpoint blockade
- (2019) Tanya E. Keenan et al. NATURE MEDICINE
- Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review
- (2019) Jean-Michel Lavoie et al. JOURNAL OF UROLOGY
- Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
- (2019) Emil Christensen et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer
- (2019) Li Wang et al. EUROPEAN UROLOGY
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
- (2019) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour lineage shapes BRCA-mediated phenotypes
- (2019) Philip Jonsson et al. NATURE
- Molecular and histopathology directed therapy for advanced bladder cancer
- (2019) Constantine Alifrangis et al. Nature Reviews Urology
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
- (2019) Aurélie Kamoun et al. EUROPEAN UROLOGY
- Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer
- (2019) Elie Ritch et al. CLINICAL CANCER RESEARCH
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
- (2019) Pedram Razavi et al. NATURE MEDICINE
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- (2019) David Liu et al. NATURE MEDICINE
- False positive plasma genotyping due to clonal hematopoiesis
- (2018) Yuebi Hu et al. CLINICAL CANCER RESEARCH
- Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis
- (2018) Karin Birkenkamp-Demtröder et al. EUROPEAN UROLOGY
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Matti Annala et al. Cancer Discovery
- Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests
- (2018) Gonzalo Torga et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sensitive tumour detection and classification using plasma cell-free DNA methylomes
- (2018) Shu Yi Shen et al. NATURE
- Detection and surveillance of bladder cancer using urine tumor DNA
- (2018) Jonathan C. Dudley et al. Cancer Discovery
- Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
- (2017) Eugene J. Pietzak et al. EUROPEAN UROLOGY
- Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer
- (2017) Emil Christensen et al. EUROPEAN UROLOGY
- Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
- (2017) Roland Seiler et al. EUROPEAN UROLOGY
- Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
- (2017) Manav Korpal et al. Nature Communications
- Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy
- (2017) Bernhard Kiss et al. Scientific Reports
- Tumor heterogeneity offibroblast growth factor receptor 3(FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
- (2016) D. Pouessel et al. ANNALS OF ONCOLOGY
- Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma
- (2016) Philippe Lamy et al. CANCER RESEARCH
- Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer
- (2016) Karin Birkenkamp-Demtröder et al. EUROPEAN UROLOGY
- Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma
- (2016) Guru Sonpavde et al. JOURNAL OF UROLOGY
- Bladder cancer
- (2016) Ashish M Kamat et al. LANCET
- Near-optimal probabilistic RNA-seq quantification
- (2016) Nicolas L Bray et al. NATURE BIOTECHNOLOGY
- Clonal evolution of chemotherapy-resistant urothelial carcinoma
- (2016) Bishoy M Faltas et al. NATURE GENETICS
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- (2016) Jacob J. Chabon et al. Nature Communications
- Clinical Validation of Chemotherapy Response BiomarkerERCC2in Muscle-Invasive Urothelial Bladder Carcinoma
- (2016) David Liu et al. JAMA Oncology
- Somatic mutation in cancer and normal cells
- (2015) I. Martincorena et al. SCIENCE
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy
- (2013) Andrea B. Apolo et al. JNCI-Journal of the National Cancer Institute
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
- (2013) Steven A Roberts et al. NATURE GENETICS
- Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
- (2011) Achim Fleischmann et al. EUROPEAN UROLOGY
- Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
- (2010) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More